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1. INTRODUCTION  
1.1 BURDEN OF HIV/AIDS IN LOW-INCOME SETTINGS 
In the last 25 years, more than 25 million people have died of Acquired Immunodeficiency 
Syndrome (AIDS). Nowadays, about 95% of people with Human Immunodeficiency Virus (HIV) 
or AIDS live in developing countries. By 2006, it was estimated that 63% of all persons infected 
with HIV are living in Sub-Saharan Africa and 72% of all adults and child deaths due to AIDS 
occurred in Sub-Saharan Africa. Moreover, in this same region and for the year 2006 alone, it is 
estimated that 2.8 million people were newly infected and 2.1 million died of AIDS. [1] [2] 
It is worth to add that the estimated average prevalence rate in this region, in the adult 
population aged between 15 to 49 year old, is 5.9% but this prevalence can exceed 20% in the 
worst-affected countries like Swaziland. The epidemic in this region is especially affecting young 
women. [1] 
1.2 ANTIRETROVIRAL TREATMENT IN LOW-INCOME SETTINGS 
1.2.1 The scaling-up of antiretroviral treatment in low-income countries 
The Highly Active Antiretroviral Therapy (HAART) is the combination of at least three 
antiretroviral compounds. The combination purpose is to reduce the likelihood of drug resistance. 
However in the long-term the resistance to the first-line combination occurs and leads to treatment 
failure. Thus, a second-line and even a third-line regimen are recommended in the long run. 
The prices decrease of antiretroviral compounds allowed the World Health Organization 
(WHO) to launch the “3 by 5 initiative” in order to promote the scale-up of antiretroviral 
treatments in low-income settings. [3] In low and middle income countries, it was estimated that by 
December 2006 some 2 million people living with HIV/AIDS were receiving treatment 
representing 28% of the estimated population in need. 
In Sub-Saharan Africa, the WHO Progress Report shows that by December 2006, 1.3 million 
people were on antiretroviral treatment, with a coverage of 28%, while three years earlier there 
were only 100 000 patients on antiretroviral therapy and the coverage reached only 2%. [4] 
1.2.2 Standardized and simplified approaches in low-income countries 
On the basis of the available Evidence Based Medicine, standardized first-line and second-line 
regimens and simplified formularies have been established by 2003 WHO guidelines, which were 
reviewed in 2006.  
The consensus for the first-line HAART is as follow: one compound from the Non Nucleoside 
Reverse Transcriptase Inhibitors class (NNRTI), generally Efavirenz or Nevirapine, supported by 
two compounds in the Nucleoside or Nucleotide Reverse Transcriptase Inhibitors (NRTI and 
NtRTI) classes like Zidovudine, Lamivudine, Emtricitabine, Tenofovir, etc. The choice of first-line 
regimens was broadened in 2006 WHO guidelines. Three new antiretroviral have been added as 
first-line compounds options: Tenofovir (TDF), Emtricitabine (FTC) and Abacavir. Tenofovir was 
previously recommended for second-line regimen. Emtricitabine is regarded as an equivalent to 
Lamivudine. [5] 
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In the management of HIV/AIDS disease, monitoring is necessary in order to determine the 
appropriate time to start the first-line antiretroviral therapy and also the right moment to stop the 
therapy and to switch to second-line therapy if available. Three main tools are available to allow a 
close monitoring of the disease progression. First, the clinical conditions determine roughly the 
disease progression. Secondly, the immunological laboratory monitoring follows the plasma CD4+ 
cells counts over time. Knowing that the CD4+ immune cells are the main target of HIV, a 
decrease in the CD4+ cells counts is correlated with the progression to AIDS or death. Thirdly, the 
virological laboratory monitoring measures the virus load (commonly referred as HIV-RNA levels 
or VL). A high VL level is correlated with the progression of the disease. 
In high-income countries, all these tools are available and an individual approach allows for 
close monitoring of disease progression and the antiretroviral therapy efficacy. In resource-limited 
settings, advanced laboratory monitoring (CD4+ counts and VL) are rarely available due to high 
costs and inadequate infrastructure. Hence, many low-income countries rely only on the clinical 
axis of the WHO clinical staging system to monitor the HAART therapy and the progression of 
the HIV/AIDS disease. It is worth to outline that this population based approach of monitoring 
disease allowed the scaling-up of antiretroviral therapies in low-income countries. 
The WHO clinical staging system is based on clinical parameters and it includes a clinical axis 
made of 32 clinical conditions divided into 4 Stages. Stage 1 includes patients who are 
asymptomatic. Stage 2 and Stage 3 are intermediate stages related to mild and advanced symptoms 
respectively. Finally, Stage 4 is associated to severe infections and symptoms. Stage 4 is equivalent 
to clinical Acquired Immunodeficiency Syndrome (AIDS). The WHO clinical stages classification is 
detailed in the Annex 1. [6] [7] [8] 
1.2.3 The current distribution of HAART use in resource-limited countries 
According to a 2006 survey conducted in 24 resource-constrained countries by Renaud Thery and 
al., the distribution of the first-line and second-line regimens use among adults was 96% and 4% 
respectively. These percentages outline the low accessibility to second-line regimen in low-income 
settings. [9] 
In addition, the survey showed that 95% of the adults receiving the first-line treatments were on 
regimens consistent with those preferred by the WHO. The most common combinations used on 
the basis of the survey are as follow: 
• Stavudine/ Lamivudine/ Nevirapine (61%) 
• Zidovudine / Lamivudine / Nevirapine (16%) 
• Zidovudine / Lamivudine / Efavirenz (9%) 
The survey confirmed that the uptake of Tenofovir and Emtricitabine, less available and more 
expensive drugs, remains low. The situation will certainly change as manufacturers and stakeholders 
work to expand access. [6] [9] 
1.3 AIMS OF THE STUDY 
1.3.1 The two treatment alternatives under comparison 
Tenofovir (300 mg) co-formulated with Emtricitabine (200mg) and Efavirenz (600 mg) currently 
known under the brand name Atripla was introduced in July 2006 in the United States market. 
The excellent safety profile and ease of use make this combination a perfect first-line regimen in 
low-income settings. Therefore, this treatment option was recommended in WHO 2006 reviewed 
guidelines. [5] Unfortunately, Tenofovir and Emtricitabine compounds are still costly and not yet 
widely available. [6] For a matter of simplification this regimen is referred in this report as “the 
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recent” therapy. 
Initially, we had in mind to consider the most frequently used first-line regimen in low-income 
countries (Stavudine/ Lamivudine/ Nevirapine) as a comparator for this economic evaluation. [9] 
Unfortunately, according to the literature review results (see Annex 3); there was no data available 
comparing head to head the effectiveness of this regimen with the recent one. Instead, we selected 
a less frequently but commonly used first-line regimen in low-income countries as a comparator: 
Zidovudine, Lamivudine, Efavirenz. [9] This combination has extensive experience in durability, 
safety and toxicity and seems to be an optimal choice for a first-line regimen according to the 
clinical trial group 384 team. [10] Furthermore, Zidovudine, one of the compounds of this 
combination is now recommended as one of the preferred NNRTI options to be considered by 
countries instead of Stavudine (the most used NNRTI in limited-income countries). [5] [9] [11] [12] As 
this combination has been included in the WHO guidelines as a first-line therapy since 2003 when 
WHO launched the “3 by 5” scaling-up initiative, this combination of drugs is referred in this 
report as the “old” therapy. [13] [14]  
1.3.2 Objectives 
The primary objective of this economic evaluation is to compare the two first-line HAARTs 
introduced above, in a low-income setting context. Both of these combinations are recommended 
by the 2006 WHO guidelines as potential first-line regimens. [5] 
The secondary objective is to provide a simplified and comprehensible cost-effectiveness 
modeling tool in order to help policy makers, in resource-limited settings, make decisions about 
which first-line HAART to fund using the scarce resources available. 
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2. MATERIALS AND METHODS 
2.1 MODEL OVERVIEW: KEY FEATURES OF THE MODEL 
Economic evaluation is the comparative analysis of alternative interventions in terms of both their 
costs and consequences. Three main types of economic evaluation are commonly used: cost-
effectiveness analysis, cost-utility analysis and cost-benefit analysis. The fundamental differences 
between these approaches remains in the methodology to measure the benefits or consequences of 
alternative health interventions (see Figure 1). [15] 
The monetary valuation of the outcomes of health-care in cost-benefit analysis, in particular the 
value of life, doesn’t reach consensus. Cost-effectiveness and cost-utility analysis are the most 
suitable approaches to compare health interventions that produce similar units of outcomes. Cost-
utility analysis is seen as a useful technique because it allows incorporating quality of life 
adjustments to treatment outcomes. Since we compare two interventions in the same therapeutic 
category, cost-effectiveness analysis and cost-utility analysis will be considered. [16] 
 
Measurements
• Direct*
• Indirect*
• Intangible* 
Integrating 
quantity and 
quality gains 
(e.g. QALYs)
Primary 
effectiveness 
measure (e.g. LY 
gained, surrogate 
endpoints)
BenefitsUtilityEffectiveness
• Direct
• Indirect
• Intangible 
Costs
HEALTH CARE
INTERVENTION
INPUTS CONSEQUENCES
CEA CUA CBA
 
Figure 1 - Potential components of economic evaluation in health care (*valued in monetary terms/ 
CEA, CUA and CBA stands for cost-effectiveness analysis, cost-utility analysis and cost-benefit analysis respectively)[15] 
[16] 
 
Economic evaluation will usually need to consider multiple factors and data from multiple 
sources. Thus, it often requires the systematic integration of data through modeling. In this study, 
modeling will be used to synthesize the available data and to relate this available evidence to the 
specific decision issue studied. [16] [17] [18]  
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Within this study, we constructed an overall model in two subsequent parts - the short and the 
long-term. First, the short-term part evaluates the costs and effects of the two alternatives over two 
years. Then the long-term element extrapolates the patient costs and outcomes beyond the first 
two years. Data for the whole model were mainly derived from a literature search of published 
clinical trials on the common medical databases (Embase, Cochrane and Medline), HIV/AIDS 
reports and health economics’ articles. It is worth to outline that the model was constructed from 
the healthcare system perspective. 
In order to reflect the low-income countries practice and to simplify the reality, the following 
assumptions had to be incorporated in the modelling:  
• It was assumed that all healthcare professionals would be fully compliant to the WHO 
guidelines and to our assumptions. 
• All patients were assumed naïve to previous antiretroviral compounds at the initiation 
of the therapy. 
• As laboratory monitoring is often unavailable in low-income setting, we assumed that 
the management of the disease and the antiretroviral treatment is based on WHO 
clinical staging system (accounting for the symptomatic criteria alone). [5] The whole 
model is founded on the basis of the four WHO clinical stages (see Annex 1).  
• According to WHO guidelines, failure (and interruption) of the therapy is defined as 
progressing to Stage 3 or Stage 4 after at least 6 months of receiving therapy. In fact, 
the severe clinical events occurring during the first 6 months are mostly due to Immune 
Reconstitution Inflammatory Syndrome (IRIS) related to pre-existing conditions. 
During these first 6 months following the initiation of the HAART, it is difficult to 
differentiate between failure and IRIS events on the basis of the WHO clinical axis. [5] 
• Due to the low accessibility to substitute first-line or second-line therapy in the low-
income settings, the model does not consider any salvage therapy in case of failure or 
major toxicity after starting one of the alternative combinations. [9] 
Costs were expressed in US dollars at 2006 price base. The study included the annual acquisition 
costs of the drugs based on Médecins sans Frontières 2007 pricing guide. We assumed in the model 
that the alternatives compared have different acquisition costs (US$ 385 per patient per year for the 
recent therapy vs. US$ 347 per patient per year for the old one). [19] We also incorporate estimations 
of the average healthcare costs associated with each year spent in a specific WHO clinical stage on 
the basis of literature findings. [20] [21] The average cost related to the transition to the death state 
was also accounted for. [22] On the contrary to the acquisition costs of HAART, healthcare costs 
related to WHO-clinical stages and the costs relative to the transition to the death state are 
assumed identical for both options. 
 On the benefits side, both Life Years (LYs) and Quality-Adjusted Life-Years (QALYs) gained 
were considered. LYs gained are calculated by summing up the years spent in all the stages 
excluding the patients that reached the death state. The advantage of the QALY as a measure of 
health output is that it can simultaneously capture gains from reduced morbidity (quality gains) and 
reduced mortality (quantity gains), and integrate these into a single measure. In order to derive the 
generic QALY outcome, the length of life gained is adjusted to the quality of life thanks to utility 
ratios attributed to each WHO clinical stage (the utility ratios vary from 0 to 1 where 0 is death and 
1 is perfect health). [16] [17] Hence, QALYs are calculated by applying these quality of life ratios to 
each year spent in a specific WHO clinical stage. These ratios are drawn from an empirical 
Ugandan study on the quality of life of HIV-infected patients. [23] [24] 
Other categories of costs and benefits such as indirect costs, intangible costs, indirect benefits 
and intangible benefits to patients are excluded from the analysis because it has not been 
performed from a societal perspective (see Figure 1). 
The whole costs and benefits where assumed to occur totally at the beginning of each year. An 
annual discount rate of 3% is adopted for both costs and outcomes values according to WHO-
 10 
2003 recommendations. [25] 
The inputs described in the paragraphs above (costs, quality of life ratios and discount rates) are 
average estimates predicated on the basis of data found in the literature for low-income countries. 
These data inputs are used for both the short and long-term parts. Details of these data inputs, 
together with their sources, are outlined in the table of the Annex 2. With the general framework of 
the overall model established, the following sections detail the descriptions of both the short-term 
and the long-term parts of the model. 
2.2 SHORT-TERM MODEL 
2.2.1 Model structure 
The short-term model is structured as a decision tree model as illustrated in Figure 2. The decision 
tree represents possible prognoses under one of the drug alternatives compared. It considers costs 
and effects over a 2-years period mirroring the follow-up period of the clinical trial considered (see 
paragraph below - data inputs). [26] [27] 
The analysis was conducted on a hypothetical cohort of 10 000 HIV-infected patients. We 
assumed the following average baseline characteristics for this cohort based on data found in the 
literature for low-income countries: 
• The patients are antiretroviral-naïve adults with the same baseline characteristics 
defined in the clinical trial except for the CD4+ count and the clinical stage at entry. [26] 
• In settings where a CD4+ cell monitoring is unavailable, WHO advises to start the 
antiretroviral drugs at an advanced stage: Stage 3 or 4. In practice, the majority of the 
patients in low-income settings start the therapy at Stage 3. [28] [29] In order to simplify 
the model, we supposed that HAART therapy was initiated at Stage 3 for all the 
patients. 
• In view of the fact that the median CD4+ count at start is lower in low-income settings 
compared to high-income countries, we assumed that the average CD4+ counts at start 
for both the alternatives hypothetical cohorts is around 108 cells /µl (instead of the 233 
and 241 cells /µl reported by the clinical trial considered, which are in the range of 
high-income countries’ levels). [30] 
2.2.2 Data source  
Efficacy data for the purpose of the short-term model comparing the two alternatives were 
identified by searches of clinical data in the following electronic databases: Medline, Embase and 
Cochrane. The research methodology details and the investigations results are outlined in the 
Annex 3 of this report.  
Two records, associated to the same initial cohort (study 934), were eligible for inclusion in the 
context of our study. [26] [27] These records compare head to head the efficacy (in term of surrogate 
endpoints) of the two alternatives after one year and two years of follow-up. It is worth to add that 
the design of this study is a prospective, randomized, open-label, non-inferiority trial. We mainly 
consider for the short-term model the results of two years of follow-up. [26] A summary of the main 
results of this clinical trial is presented in the Annex 4.  
Succinctly, the study reported these two main conclusions: 
•  “Over 96 weeks, the combination of TDF/FTC/EFV was superior to fixed dose of 
ZDV/3TC/EFV for achieving and maintaining an HIV RNA level < 400 copies/mL 
and an increase in CD4 cells.” [26] 
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• “Through 96 weeks, significantly more patients in the ZDV/3TC/EFV group 
experienced adverse events that resulted in discontinuation of study medications (11% 
in the ZDV/3TC group vs. 5% in the TDF + FTC + EFV group).” [26] 
The clinical study reports the efficacy of the two regimens as the percent of patient with a VL 
below 400 copies/mL. In fact, VL is a good predictor of progression of the disease to AIDS or 
death. [31] Unfortunately, there is no global clear equation translating VL measurements into the 
probable clinical progression of the disease, according to medical experts consulted (Mme Valérie 
Journot – Institut de Santé publique, d’épidémiologie et de développement – Bordeaux – France). 
2.2.3 Data adjustments and assumptions 
The clinical trial selected mirrors the presumable health efficacy in high-income countries and are 
unlikely to provide reliable estimates for low-income countries where the management of the 
disease is different. [27] Moreover, the results reported are in terms of viral load measurements 
(which are not available in our study setting), instead of WHO-clinical stages reached. Therefore, 
clinical trial results were processed and rearranged to reflect the differences of practice and 
effectiveness in low-income settings given the following assumptions: 
• We assume that patients, who reached a viral load below 50 copies per mL (meaning 
that the therapy for the set of patients is very efficient,) are attributed to Stage 1. 
• Patients achieving a viral load lower than 400 copies/mL but above 50 copies/mL or 
patients that achieved a viral load below 50 copies/mL during the first year but did not 
consent to continue the therapy the 2nd year, are attributed to Stage 2. 
• We conservatively judged that all non responders to the therapy and missing data to 
represent treatment failure. We also included in this node of the tree, patients that were 
tested to be initially resistant to NNRTI (Efavirenz) who were not accounted in the 
clinical trial results. In fact, we assume that no laboratory monitoring is available to 
detect initial resistance in our study setting. Then, for this entire portion of non-
responders the treatment is maintained for 6 months as mentioned in the WHO-
guidelines. [5] We suppose that no benefit is accounted from these 6 months of 
antiretroviral treatment. As we assume that no replacement treatment is available, these 
patients will then progress according to the natural history of the disease without 
antiretroviral treatment. Hence, these patients will remain in Stage 3 or progress to 
Stage 4 or death according to probabilities drawn from the literature. [32] 
• Patients starting HAART in resource-limited settings have increased morality rates in 
the first months on therapy, compared with those in developed countries. [30] It is partly 
explained by the lower baseline CD4+ counts at start of the treatment. In order to 
include this difference in mortality rate, we consider that in our model patients are 3,41 
times more likely to die than reported in the clinical trial. [33] The deaths estimated from 
this adjustment are extracted from the responders in Stage 1 (patients reaching a VL 
below 50 copies /mL). 
These adjustments and assumptions are also illustrated in Figure 2. After their incorporation to 
the clinical trial data mentioned above, we obtain the transition probabilities for the decision tree 
(depicted in Annex 5). 
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Transition probabilities for the “Recent therapy” = a: 0,589 / b: 0,118 / c: 0,082 / d: 0,094 / e: 0,117; 
Transition probabilities for the “Old therapy” = a: 0,536 / b: 0,055 / c: 0,118 / d: 0,134 / e: 0,157 
 
Figure 2 - Structure of the short-term part of the model including the assumptions and clinical 
trial data adjustments incorporated  
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2.3 LONG-TERM MODEL 
The purpose of the long-term part of the model is to extrapolate the costs and the effects beyond 
the two years follow-up period of the clinical trial.  
2.3.1 Model structure 
In this part of the model, we use a Markov model approach in order to handle the complexity of 
modeling options with the multiplicity of possible consequences for patients on HAART therapy 
in the long-term. This Markov model characterizes a patient’s prognosis in terms of five states. 
Thus, the long-term model is based on a five-compartment Markov model as depicted in Figure 3. 
Four of these are based on the four WHO-clinical stages. The last state is the death absorbing state. 
Portions of the initial cohort distribution of patients (obtained after running the short-term part of 
the model) run through the model according to transition probabilities that govern how likely it is 
to transit from one state to another.  
2.3.2 Data source 
Probability data, determining how proportion of patients move between states, was derived from 
an observational study in Uganda reporting the natural disease progression. [32] A summary of the 
main results of this study is shown in the Annex 6.  
2.3.3 Data adjustments and assumptions  
In this part of the model, we conservatively assumed that both the alternatives ceased to confer 
major health improvements after the two years under treatment of the short-term part. We 
supposed, in the long-term part, that patients can only remain in the same state or progress to a 
more severe state. However, we assumed that the HAART therapy confers a minor benefit by 
delaying the progression of the disease.  
Moreover, we run this part of the model with the following hypothesis: 
• We use the same transition probabilities for the two alternatives, as we assumed that 
the major health benefits already occurred during the short-term part of the model. 
• Each Markov cycle is taken as 1year. 
• All transition probabilities are assumed to take place at the start of the cycle. 
• No discontinuation due to acute toxicity is considered. In fact, discontinuation of the 
therapy due to major adverse events occurs mainly in the first-year under HAART and 
very few patients interrupted the therapy in the second year of follow-up. [26] [27] 
• No discontinuation due to chronic toxicity is accounted even if these kinds of adverse 
events may appear in the long-run and may lead to the interruption of the therapy (e.g. 
lipodystrophy).  
• As in the short-term model, we consider that the therapy is interrupted when patients 
have entered Stage 3 or 4, and that no salvage therapy is initiated. 
The transition probabilities governing the direction and speed of transitions between disease 
states in the Markov model are shown in Annex 7. [32] In view of the lack of data, especially 
concerning Stage 1 and Stage 2, some probabilities were roughly estimated and will be tested in the 
sensitivity analysis. (See Annex 7) 
The transition probabilities are assumed fixed with respect to time and the Markov model is run 
until almost 90% of the initial hypothetical cohort of 10 000 patients has entered the death 
absorbing state. 
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Figure 3 - Structure of the long-term part of the model (the decimal numbers are the base-case 
transition probabilities) 
 
2.4 ANALYTICAL METHODS 
2.4.1 Computation  
The model was developed in Excel - Microsoft Office 2003. The results of the model are presented 
in term of costs (US$), Life Years gained (LY) and Quality-Adjusted Life-Years (QALYs) gained. 
The two therapies are then compared, calculating the Incremental Cost-effectiveness Ratios 
(ICERs) in terms of cost per life year gained (US$/LY) and in terms of cost per quality-adjusted 
life-year gained as well (US$/QALY). The results of both the short-term model alone and the 
overall model (combining the results of the short-term part and the long-term part) are presented.  
2.4.2 Sensitivity analysis 
A number of one-way sensitivity analyses were undertaken to assess the robustness of the results of 
the base-case analysis to variations in the data inputs and assumptions. The sensitivity analyses were 
divided into three main sections: 
First, we varied some cost inputs:  
 
 
 
S1
S2 S3
S4
DEATH
Absorbing State
0,100 
0,199 
0,029 
0,023 
0,095 
0,190 
0,620 
0,095 0,186 
0,195 
0,612 
0,388 
0,619 
0,649 
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• The acquisition costs of the combinations according to different manufacturers prices 
published in the MSF report. [19] 
• The average healthcare costs associated with Stage 2 and Stage 3. 
Secondly, as recommended by the WHO-CHOICE guidelines, we altered the discount rates. 
Thus, discount rates of 6% for costs and 0% for benefits were applied instead of the 3 % discount 
rates in the base-case. [25] 
Finally, we modified some transition probabilities and assumptions: 
• In the short-term, we assumed that all responders were attributed to Stage 2, even 
patients that achieved a viral load below 50 copies/mL. Thereby, we supposed that no 
patient progressed to Stage 1. 
• In the long-term part, we varied some transition probabilities associated with Stage 1 
and Stage 2 that were roughly estimated in the base-case. 
Annex 8 summarizes the parameters used in the base-case analysis and how these were varied in 
the sensitivity analyses. 
 Using the results of the overall model sensitivity analyses, ICER elasticities, associated with the 
variation of some input variables, were calculated. The elasticity of the ICER was defined as the 
percentage variation of the ICER (in terms of US$/QALY) over the percent change in the input 
parameter varied. The calculation of the ICER elasticity is detailed in the following equation: 
 
 
BC
BCSA
BC
BCSA
Parameter
ParameterParameter
ICER
ICERICER
e )(
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−
−
=  
Where: 
e is the ICER elasticity associated with the variation of an input variable 
ICER SA  is the overall model ICER (in terms of US$/QALY) of the sensitivity analysis considered 
ICER BC  is the overall model ICER (in terms of US$/QALY) of the base-case 
Parameter SA is the value of the parameter varied in the sensitivity analysis 
Parameter BC  is the base-case value of the parameter varied in the sensitivity analysis  
 
 
It is worth to note that the larger the elasticity, the greater the impact of the variable on the 
ICER. 
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3. RESULTS 
3.1 BASE-CASE RESULTS 
3.1.1 Short-term part results 
Table 1 and table 2 present the base-case results for the short-term part of the model. After two 
years under HAART, patients under the recent antiretroviral treatment have higher overall costs 
and higher overall benefits (both in terms of QALYs and LYs) compared to patients under the old 
treatment. The ICERs of the recent regimen compared to the old regimen are 1289 $US/LY and 
898 $US/QALY. It is worth to outline that the use of QALY instead of LY as an outcome 
measure results in a decrease in the ICER. This difference arises from the fact that the new therapy 
confers higher benefits in term of QALYs than in term of LYs: 0,1132 QALY gained vs. 0,0788 
LY gained for one patient.  
 
Table 1 - Results of the short-term part (base-case) for the 10 000 patients cohort 
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy  16614 10159 5460633 
Recent therapy  17403 11291 6477185 
Difference 788 1132 1016552 
1289 $US/LY  
898 $US/QALY 
 
Table 2 - Results of the short-term part (base-case) for 1 patient 
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy  1,6614 1,0159 546,0633 
Recent therapy  1,7403 1,1291 647,7185 
Difference 0,0788 0,1132 101,6552 
1289 $US/LY  
898 $US/QALY 
 
3.1.2 Long-term part results 
Table 3 and table 4 detail the results of the long-term part of the model. As noticed for the short-
term part, the recent regimen confers higher benefits and costs compared to the old regimen. On 
the opposite of the short-term part, the outcomes difference between the two alternatives in term 
of QALYs is lower than the outcome difference in terms of LYs. It results in an ICER in terms of 
LYs (503 $/LY) lower than the ICER in terms QALYs (721$/QALY). Besides, it is worth to add 
that in terms of cost per QALY gained no significant variation is observed compared to the short-
term part. 
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Table 3 - Results of the long-term part of the model (base-case) for the 10 000 patients cohort 
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy  32891 18942 8138684 
Recent therapy  36243 21279 9824252 
Difference 3352 2337 1685567 
503 $US/LY  
721 $US/QALY 
 
Table 4 - Results of the long-term part of the model (base-case) for 1 patient 
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy  3,2891 1,8942 813,8684 
Recent therapy  3,6243 2,1279 982,4252 
Difference 0,3352 0,2337 168,5567 
503 $US/LY  
721 $US/QALY 
 
3.1.3 Overall model results 
Table 5 and table 6 summarize the results of the overall model (short-term combined to the long-
term). Once again, the recent combination confers higher costs and benefits compared to the old 
regimen. The difference in benefits between the two alternatives is lower if considering QALY 
instead of LYs as outcome measure. It results in an ICER in terms of US$ per QALYs gained 
greater than the ICER in terms of US$ per LYs gained. 
In summary, the results from base-case analysis demonstrate that if the health system is 
prepared to pay $653 per additional LY and $779 per additional QALY, then the choice of the 
recent combination as the first-line regimen instead of the old combination would be optimal (this 
conclusion is from a pure economic perspective and on the basis of purely competitive market 
hypothesis). 
 
Table 5 - Results of the overall model (base-case) for the 10 000 patients cohort 
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy 49505 29101 13599317 
Recent therapy  53646 32570 16301437 
Difference 4140 3469 2702120 
653 $US/LY  
779 $US/QALY 
 
Table 6 - Results of the overall model (base-case) for 1 patient  
Strategies LY gained QALYs Costs ($US) ICER 
Old therapy 4,9505 2,9101 1359,9317 
Recent therapy  5,3646 3,2570 1630,1437 
Difference 0,4140 0,3469 270,2120 
653 $US/LY  
779 $US/QALY 
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3.2 SENSITIVITY ANALYSIS RESULTS  
Table 7 presents the main results of the sensitivity analyses undertaken for the short- term part and 
the overall model. More detailed results of the sensitivity analyses are reported in Annex 9 and 
Annex 10. In the purpose of quantifying the impact of some variables on the model results, 
elasticities were computed. The details of these calculations are outlined in table 8. For instance the 
elasticity of 4.84 (depicted for the recent therapy acquisition cost) translates that a 1% increase of 
recent therapy acquisition cost will affect the overall ICER by a 4.84% increase. This high elasticity 
value reveals that the model is highly sensitive to this specific input variable. We have to keep in 
mind that the larger the elasticity in term of absolute value, the greater the impact of the variable on 
the ICER.  
The results show that the ICERs were slightly sensitive to variations in Stage 2 and Stage 3 
healthcare costs (with elasticities of 0.03 and 0 for the selected examples - see table 8). Moreover, 
the sensitivity analyses on the discount rates have a small impact on ICERs for both the short-term 
part and the overall model (with elasticities of -0.08 and 0.09 for the selected parameters varied - 
see table 8).  
However, ICERs were mildly sensitive to assumptions regarding the transition probabilities 
associated to the short-term and the long-term part of the model. But, the most influential of the 
base-case parameters were the acquisition costs of the two HAART combinations. In fact, the 
ICERs (in term of QALYs or LYs as outcome measure) were extremely sensitive to variations in 
therapies acquisition costs. For instance, the increase of the new therapy acquisition cost (from 
$385 to $487 per year per patient) resulted in more than a two fold increase of the ICERs. This 
result is also outlined by the large ICER elasticities obtained when varying the acquisition costs of 
the therapies compared (elasticities of 4.84 and -3.83 for the selected values - see table 8). 
Overall, few of the sensitivity analyses undertaken resulted in significant variation in the ICERs. 
These results outline the robustness of our model to some of the parameters investigated, but also 
emphasize the importance of accurately reporting the acquisition costs of the therapies in order to 
fully strengthen the uncertainty about our model results. 
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Table 7 - Results of the sensitivity analyses using data summarized in Annex 8 
Short-term Part 
Overall model (Short-
term + Long-term) 
RESULTS 
 
PARAMETERS  
VARIED (see Annex 8) ICER 
$/LY 
ICER 
$/QALY 
ICER 
$/LY 
ICER 
$/QALY 
No parameters varied - Base Case 1289 898 653 779 
 
COSTS VALUES  
  
Recent combination acquisition costs   
487 vs. 385 $ 3283 2286 1490 1778 
613 vs. 385 $ 5743 4001 2524 3013 
Old combination acquisition costs   
410 vs. 347 $ 195 136 199 237 
434 vs. 347 $ - 222 - 154 26 31 
Stages healthcare costs   
Stage 2 healthcare costs 0 vs. 30 $ 1242 865 632 755 
Stage 3 healthcare costs 100 vs. 70 $ 1262 879 653 779 
 
DISCOUNT RATES VALUES 
  
Cost discount rate (6% vs. 3%) 1268 884 602 718 
Benefit discount rate (0% vs. 3%) 1271 881 577 710 
 
TRANSITION PROBABILITIES  
  
Short-term part assumption (no S1 
progression) 1329 1167 634 889 
Long-term part - a lower S1 to S1  and S2 
to S2 transition probabilities : 0.50 vs. 0.6 - - 574 733 
Long-term part - a lower S1 to S1  and S2 
to S2 transition probabilities : 0.20 vs. 0.6 - - 493 681 
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Table 8 - ICER elasticities associated with the variation of some input parameters   
 Parameters values ICER ($/QALY) for 
the overall model 
Elasticities 
Parameters varied Base-case 
 
Sensitivity 
analysis 
Base-case Sensitivity 
analysis - 
Recent combination 
acquisition costs  385 $ 487 $ 779 1778 4.84 
Old combination 
acquisition costs  347 $ 434 $ 779 31 - 3.83 
Stage 2 healthcare costs  30 $ 0 $ 779 755 0.03 
Stage 3 healthcare costs   70 $ 100 $ 779 779 0 
Cost discount rate  3% 6% 779 718 - 0.08 
Benefit discount rate  3% 0% 779 710 0.09 
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4. DISCUSSION AND LIMITATIONS 
4.1 COST-EFFECTIVENESS ANALYSIS IN DECISION MAKING 
From the healthcare system perspective, the model clearly predicts that the implementation of the 
“recent” Tenofovir/Emtricitabine/Efavirenz combination as a first-line regimen to treat HIV in 
scarce-resource countries will be both more effective and more expensive than the “old” 
Zidovudine/Lamivudine/Efavirenz combination. The base-case analysis predicts an incremental 
cost-effectiveness ratio of $653 per LY gained and $779 per additional QALY gained in the long-
term. 
The cost-effectiveness ratio is a measure of value for money. Hence, the question to be 
considered would be if the healthcare systems are disposed to afford this amount of money for this 
gain in effectiveness (cost per additional LY or cost per additional QALY). Nowadays, there is no 
evidence that any health system, in low-income countries, has implemented explicit cost-
effectiveness ratio thresholds. [35] However, the 2002 World Health Report proposed a quite 
universal definition of threshold ratios below which an intervention would be considered cost-
effective. It suggests that intervention with a “cost effectiveness ratio less than the per capita GDP 
for a given country would be considered as ′′highly cost-effective′′ and less than three times the per 
capita GDP would be considered as ′′cost-effective′′ ”. [36] In light of this cost-effectiveness 
threshold definition, we report on table 9 the GDP and 3 times GDP per capita of a random 
subset of low-income countries with a high prevalence of HIV. [37] Based on the base-case overall 
model results ($779/QALY) and according to this threshold definition, the “recent” combination 
(long-term use) as compared to the “old” combination is expected to be highly cost-effective for 
some low-income countries such as Kenya, Mozambique and Zambia. On the contrary, it is not 
expected to be highly cost-effective in Malawi (see table 9).  
We have to be aware to the fact that these thresholds are not well defined. In fact, this 
thresholds’ definition do not specify the types of costs to include in calculating the cost-
effectiveness ratio (which depend on the perspective adopted). [35] [36] Furthermore, it is worth to 
outline that the cost-effectiveness ratio is not the only criteria to be considered in decision making. 
Many other factors influence priority setting such as equity (especially in low-income countries), 
opportunity costs within or outside the healthcare sector (e.g. prevention of transmission), the 
acceptance of the treatment and the affordability. [17] 
Table 9 - Theoretical thresholds values according to the WHO Report 2002  
Country 1 * GDP (PPP) per capita   3 * GDP (PPP) per capita 
Kenya 1357 4071 
Malawi 706 2118 
Mozambique 1494 4482 
Tanzania 806 2418 
Zambia 1087 3261 
GDP (PPP) per capita: Gross domestic product based on purchasing power-parity per 
capita (2006 – current international dollar) – Source: International Monetary Fund. [37] 
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4.2 LIMITATIONS: A NEED TO STRENGTHEN HEALTH DATA MANAGEMENT  
The model developed is kept as simple as possible in order to make it understandable to decision 
makers. However, this simplification is associated with several limitations. 
The model greatly simplifies reality and is based on two highly conservative assumptions. First, 
for the short-term part, we conservatively assumed that patients reaching low viral load ranges will 
automatically progress to better WHO clinical stages. Secondly, we also postulated the hypothesis 
of “one time benefit” of the HAART therapy. In fact, we assumed that the therapy confers major 
health improvements only within the two first years under treatment (possible transition to better 
health states in the short-term part) and only minor benefits within the long-term part (slow-down 
of disease progression). These two assumptions may be regarded as too conservative and should be 
revisited as new information emerges especially additional findings concerning the viral load as 
surrogate endpoint and the long-term benefits of HAART therapy in low-income settings.  
Another important restriction in the long-term part model relates to what is known as the 
memoryless feature of the Markov model. In fact, the transition probabilities depend only upon the 
health state patients are in and not on how long they had been in this health state or on the 
pathway followed to reach a specific health state. Incorporating time dependency into transition 
probabilities should be considered in further development of the model (in light of data on the 
long-term benefits of HAART). [16] [17] 
In addition, in view of the scarcity of published data available many other limitations arise from 
our model: 
• Data is combined from various sources and roughly estimated. We have to be careful to 
the fact that effectiveness and cost data may vary substantially across and within low-
income countries.  
• Effectiveness data incorporated was based on controlled clinical trials data that may 
not, even with the adjustments incorporated, mimic reliably the real-life clinical 
outcomes. 
• There is a paucity of data concerning the healthcare costs especially in low-income 
countries. One should be particularly careful in accurately reflecting the price paid for 
the drugs as our model is extremely sensitive to this parameter. This finding is 
correlated with the fact that HAART drugs amount for more than half of the cost of 
treatment of HIV-patients. [38] 
Finally, some major HIV/AIDS issues were not captured in the perspective of this analysis as a 
matter of simplification and could be included in future improvements of this model, including:  
• Productivity costs: In fact, antiretroviral therapy results in a gain of years of 
productivity and this is of major importance in countries with high prevalence of HIV 
within the working population. [39] 
• We did not consider the disease transmission factor (external benefit): HAART lower 
the VL in HIV+ individuals, thereby reducing the probability of HIV transmission to 
others. However, at the same time it prolongs the survival of potential infective hosts. 
[40] We lack data about the exact impact of this external benefit. 
• The impact of adherence to HAART therapy on its effectiveness. The new 
combination is the first once daily pill for the treatment of HIV and this is certainly of 
importance in promoting adherence and thus effectiveness especially in scarce-resource 
settings. 
Overall, it seems that the most important limitation that arises from our study is the limited 
availability of reliable data related to low-income countries. These limitations mean that 
interpretation and generalizations of the results should be viewed with caution. Because of the 
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scarcity of relevant data, approximations for many variables and assumptions were used in our 
model. These findings emphasize the need to develop health data management in low-income 
countries. More robust country estimates and additional research on the assumptions incorporated 
can result in more accurate and reliable estimates of the cost-effectiveness results obtained.  
 
 24 
5. CONCLUSION 
In conclusion, the results of this model suggest that the Tenofovir/Emtricitabine/Efavirenz 
combination, newly introduced as first-line regimen, is expected to be cost-effective relatively to 
the Zidovudine/Lamivudine/Efavirenz combination in some low-income countries.  
However, additional data about viral load as surrogate endpoints, lifetime benefits of HAART, 
and more precise country-specific data on effectiveness and costs, are needed to fully strengthen 
the uncertainty about this economic model of antiretroviral therapies in low-income countries.  
Hence, this study provides a simplified and understandable “framework” model that may be 
used, incorporating more accurate country-data, to assess the cost-effectiveness of new 
antiretroviral drugs in low-income countries.  
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6. ANNEXES 
6.1 ANNEX 1: WHO CLINICAL STAGING FOR ADULTS AND ADOLESCENTS 
Table A1 – WHO clinical staging for adults and adolescents for HIV infection [8]  
WHO clinical Stages Symptoms classification 
Examples of clinical events 
associated 
Stage 1  Asymptomatic • Painless lymph nodes 
Stage 2  Mild 
 
• Recurrent bacterial upper 
respiratory tract infection 
• Herpes zoster 
• Fungal nail infection 
• Seborrhoeic dermatitis  
 
Stage 3  Advanced 
 
• Oral candidiasis 
• Pulmonary tuberculosis 
• Severe bacterial infection 
 
Stage 4  Severe 
 
• Recurrent bacterial 
pneumonia 
• Chronic herpes simplex 
virus 
• Oesophageal candidiasis 
• Extrapulmonary 
Tuberculosis 
• Meningitis 
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6.2 ANNEX 2: PARAMETERS USED IN THE WHOLE MODEL AND SOURCES 
Table A2 – Overall model base-case parameters 
Items Values 
(Base 
case) 
Source 
of Data 
Notes 
Antiretroviral drugs 
acquisition costs of 
treatment per patient per 
year (US$) 
- MSF 
Prices listed are quoted as sale prices by 
the manufacturers. These prices does not 
include add-ons as import taxes or 
distribution mark-ups 
ZDV-3TC-EFV (old regimen) 385 [19] 
TDF-FTC-EFV (new regimen) 347 [19] 
For the base-case, we consider the 
lowest prices provided by the 
cheapest producer for low-income 
countries.  
Healthcare costs associated 
with WHO clinical Stages 
per patient per year US$ 
  
Due to the paucity of data in the 
published literature, we estimate roughly 
these costs - expecting increased 
healthcare costs for later stages of the 
disease. Some of these data inputs and 
their impact on results of the model will 
be investigated in the sensitivity analysis. 
Healthcare costs - Stage 1 0 - Estimate 
Healthcare costs - Stage 2 30 - Estimate 
Healthcare costs-  Stage 3 70 - Estimate 
Healthcare costs - Stage 4 150 [20] [21] Data are from Kenya 
Costs related to the transition 
to the death state (palliative 
care) 75 [22] 
Costs derived from estimates, using data 
from Sub-Saharan African countries. It 
was assumed that it was completely 
incurred in the last year of life. 
Quality adjustment of life 
years per year spent in a 
specific WHO clinical Stage 
  
Parameters drawn from an empirical 
study of the quality of life from Uganda. 
For one year spent in Stage 1  1 [23] [24] 1 year spent in Stage 1 is taken to be 1 
For one year spent in Stage 2 0,7 [23] [24] 1 year spent in Stage 2 is taken to be 0,7 
For one year spent in Stage 3 0,45 [23] [24] 1 year spent in Stage 3 is taken to be 0,45 
For one year spent in Stage 4 0,15 [23] [24] 1 year spent in Stage 4 is taken to be 0,15 
Discount rates per year  WHO - 
Effects discount rate (LYs and 
QALYs) 3% [25] 
- 
Costs discount rate  3% [25] - 
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6.3 ANNEX 3: LITERRATURE REVIEW  
6.3.1 Objective 
The systematic research subsequently described aims at identifying the major relevant outcome 
research publications that compares head to head the two alternatives of interest in this study. 
Adjusted results of these publications are to be used in the cost-effectiveness analysis comparing 
these two regimens. 
As mentioned in the introduction of this report, the two combinations compared are: 
• Zidovudine, Lamivudine, Efavirenz 
• Tenofovir, Emtricitabine and Efavirenz. The commonly used medical abbreviations 
used for these compounds are respectively as follow: TDF, FTC and EFV. 
6.3.2 Criteria for considering studies 
We only selected studies that included the following criteria: 
• Type of intervention: Studies comparing Tenofovir, Emtricitabine and Efavirenz 
combination to the Zidovudine, Lamivudine and Efavirenz combination. 
• Type of studies: Randomized studies. 
• Type of participants: Adults and/or adolescents aged 15 years old or more without 
prior exposure to antiretroviral therapy. 
• The study also has to report at least one of the following primary or secondary 
outcome measures  
o Primary outcomes measures: death or AIDS defining illness, proportion of 
patients that discontinued the 1st line combination therapy, time to withdrawal 
of the 1st line therapy, survival (time to death), virologic failure rates. 
o Secondary outcomes: CD4+ cells counts changes compared with a baseline 
mean, proportion of patients reaching defined viral load levels, quality of life 
indicators, any major or minor adverse events. 
6.3.3 Search methodology 
As the recent combination is the limiting search criteria, we based the quest on the recent 1st line 
combination drugs names. We searched the following major electronic database: 
• Medline via PubMed using the following search terms (drug commonly used names and 
abbreviations) joined with the “AND” and “OR” Boolean operators. The search was 
performed on the 7th of September 2007 using the following research string: 
(Tenofovir OR TDF) AND (Emtricitabine OR FTC) AND (Efavirenz OR EFV) 
• A similar search strategy was performed on the Cochrane Library (2007/Issue3) on the 
7th of September 2007. The search was separately applied on titles, abstracts and key 
words. 
• Using the same search strategy, a research was performed on EMBASE Database 
(records from 1989 to 08/2007) through ERLWebSPIRS research interface on the 10th 
of September 2007. The research was applied separately on titles and keywords.  
In order to limit the results obtained from the EMBASE database search on keywords, 
 28 
we applied an advanced search strategy on keywords as well. For this purpose, we 
combined the search terms used previously with terms specific to the type of the study 
(terms related to randomized clinical trials) and to the health condition of interest 
(terms related to HIV). Thus, we investigated the keywords of the EMBASE database 
with the following advanced research string: 
“(Tenofovir OR TDF) AND (Emtricitabine OR FTC) AND (Efavirenz OR EFV) 
AND (clinical trial OR randomized trials) AND (AIDS OR HIV OR Immune 
deficiency)” 
6.3.4 Results of the databases searches 
The searches in the three databases yielded to the following results: 
In the Medline database, 46 records were found. On the basis of the titles and/or the abstracts 
(if available), five publications were considered potentially relevant and selected for full article 
retrieval. The two following publications were found to be the most relevant for the purpose of 
our study: 
1. Pozniak AL, Gallant JE, DeJesus E, Arribas JR, Gazzard B, Campo RE, et al. 
Tenofovir disoproxil fumarate, Emtricitabine, and Efavirenz versus fixed-dose 
Zidovudine/Lamivudine and Efavirenz in antiretroviral-Naïve Patients: 
virologic, Immunologic, and morphologic changes – a 96-week analysis. J. 
Acquir. Immune Defic. Syndr. 2006; 43 (5):535-40. 
2. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. Tenofovir 
DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz 
for HIV. N. Engl. J. Med. 2006; 354 (3) :251-60.  
The Cochrane Library search yielded to two records in total. The two publications found were 
already identified through the previous Medline database search. 
Finally, the Embase research applied on titles identified six records from which two were 
relevant. The two publications were the ones identified through the Medline Database search. The 
Embase search applied on the keywords yielded 606 records in total. Instead of reviewing all these 
records, we applied the advanced search strategy described above, which identified 71 records. On 
the basis of the titles and/or abstract review none of these publications were relevant to the 
purpose of our study. 
In summary, two records were eligible for inclusion in the context of our study. These two 
publications quoted above are related to the same cohort (study 934 Group) respectively after one 
year and 2 years of follow-up. The design of this clinical trial is a prospective randomized, open-
label, non-inferiority trial. 
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6.4 ANNEX 4: MAIN RESULTS OF THE CLINICAL TRIAL CONSIDERED  
Table A4 – Main results of the clinical trial considered in the short-term part of the model [26] 
 TDF/FTC/EFV “recent” ZDV/3TC/EFV “old” 
Responders: Portion of patients 
achieving and maintaining 
virologic suppression below:  
  
< 50 copies/mL HIV RNA 67% (ns) 61% (ns) 
< 400 copies/mL HIV RNA 75% 62% 
Proportion of patients who 
discontinued the study 
medications due to : 
  
Adverse events  5% 12% 
ns: not statistically significant difference 
 
 
 
 
6.5 ANNEX 5: BASELINE PROBABILITIES IN THE SHORT-TERM PART 
Table A5 – Baseline probabilities used in the short-term part of the model 
Transition probabilities 
From S3 (initial state) to: 
“Recent therapy” 
TDF/FTC/EFV 
“Old therapy” 
ZDV/3TC/EFV 
to S1 0,589 0,536 
to S2 0,118 0,055 
to S3 0,082 0,118 
to S4 0,094 0,134 
to death 0,117 0,157 
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6.6 ANNEX 6: RESULTS CONSIDERED IN THE LONG-TERM PART  
Table A6 – Main results of the publication considered in the long-term part of the model [32] 
Prevalent and incident cases Four years Cumulative 
probability of entering Stage 
4 (95% CI) 
Four years cumulative 
probability of death (95% 
CI) 
Entered Stage 1 0.11 0.09 
Entered Stage 2 0.33 0.33 
Entered Stage 3 0.58 0.56 
Entered Stage 4 - 0.86 
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6.7 ANNEX 7: ANNUAL TRANSITION PROBABILITIES USED IN THE LONG-
TERM MODEL  
Table A7 – Markov annual transition probabilities derived from observational data in Uganda [32] 
Description Transition 
probabilities for the 
base-case 
Source and Notes 
to Stage 1 0.649 Assumption* Ω 
to Stage 2 0.199 Assumption* Ω 
to Stage 3 0.100 Assumption* 
to Stage 4 0.029 [32]** 
From Stage 1 
to death  0.023 [32]** 
to Stage 2  0.620 Assumption* Ω 
to Stage 3 0.190 Assumption* Ω 
to Stage 4 0.095 [32]** 
From Stage 2 
to death 0.095 [32]** 
to Stage 3 0.619 Calculation : 1-(0.195+0.186) 
to Stage 4 0.195 [32]** From Stage 3 
to death 0.186 [32]** 
to Stage 4 0.612 Calculation : 1- 0.388 
From Stage 4 
to death 0.388 [32]** 
* These estimates will be tested in the sensitivity analysis 
** [34] Assuming a fixed rate with respect to time, the one year probabilities were derived from the 
four year probability shown on Annex 6 using the following formula: One year probability = 1-exp 
[1 year*(ln(1-“Four year probability”))/4 year] 
Ω These transition probabilities were estimated on the basis of the transition probabilities of 
remaining in Stage 3 and the transition probability of moving from Stage 3 to Stage 4. 
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6.8 ANNEX 8: PARAMETERS VARIED IN THE SENSITIVITY ANALYSES 
Table A8 – Values of the parameters varied in the sensitivity analyses 
Elements Base-case inputs Variations in 
sensitivity analysis 
Sources 
Costs 
Acquisition costs of the 
“recent” drug combination  
385 487 or 527 or 613 MSF [19] 
Acquisition costs of the “old” 
drug combination 
347 410 or 420 or 434 MSF [19] 
Healthcare costs  associated 
with Stage 2 
30 0 Assumption 
Healthcare costs associated 
with Stage 3 
70 100 Assumption 
Annual Discount rates 
Costs discount rate  3% 6% WHO [25] 
Benefits discount rate 3% 0% WHO [25] 
Transition probabilities and assumptions 
Short-term part: 
All respondent achieving a 
viral load below 400 copies 
per mL are attributed to Stage 
2 ( none to Stage 1) 
Old therapy: 
* S3 to S1 node: 0.536 
* S3 to S1 node: 0.055 
New therapy:  
* S3 to S1 node: 0.589 
* S3 to S1 node: 0.118 
Old therapy: 
* S3 to S1 node: 0 
* S3 to S1 node: 0.591 
New therapy:  
* S3 to S1 node: 0 
* S3 to S1 node: 0.707 
Assumption 
Long-term part: 
Transition probabilities 
associated with Stage 1 and 
Stage 2 
Stage 1 probabilities: 
*S1 to S1: 0.649 
*S1 to S2: 0.199 
*S1 to S3: 0.100 
Stage 2 probabilities: 
*S2 to S2: 0.620 
*S2 to S3: 0.190 
Stage 1 probabilities: 
*S1 to S1: 0.50 
*S1 to S2: 0.224 
*S1 to S3: 0.224 
Stage 2 probabilities: 
*S2 to S2: 0.50 
*S2 to S3: 0.31 
Assumption 
Long-term part: 
Transition probabilities 
associated with Stage 1 and 
Stage 2 
Stage 1 probabilities: 
*S1 to S1: 0.649 
*S1 to S2: 0.199 
*S1 to S3: 0.100 
Stage 2 probabilities: 
*S2 to S2: 0.620 
*S2 to S3: 0.190 
Stage 1 probabilities: 
*S1 to S1: 0.20 
*S1 to S2: 0.37 
*S1 to S3: 0.37 
Stage 2 probabilities: 
*S2 to S2: 0.20 
*S2 to S3: 0.61 
Assumption 
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6.9 ANNEX 9: RESULTS OF THE SENSITIVITY ANALYSES FOR THE SHORT-
TERM PART 
Table A9 – Results of the sensitivity analyses (short-term part) using data summarized in Annex 8 
Element 
Values 
varied 
Base 
case 
inputs 
Strate
gy 
LYs 
gained 
QALYs 
gained 
Costs ICER 
None - Old  16614 10159 5460633 
Base case  
None - Recent  17403 11291 6477185 
1289 $/LY 
898 $/QALY 
Costs 
Old  16614 10159 5460633 
487 385 
Recent  17403 11291 8047891 
3283 $ /LY 
2286 $/QALY 
Old  16614 10159 5460633 
527 385 
Recent  17403 11291 8663854 
4063 $ /LY 
2830 $/QALY 
Old  16614 10159 5460633 
Recent 
therapy Drug 
costs 
613 385 
Recent  17403 11291 9988175 
5743 $ /LY 
4001 $/QALY 
Old  16614 10159 6323283 
410 347 
Recent  17403 11291 6477185 
195 $ /LY 
136 $/QALY 
Old  16614 10159 6460212 
420 347 
Recent  17403 11291 6477185 
22 $/ LY 
15 $/QALY 
Old  16614 10159 6651912 
Old therapy 
Drug costs 
434 347 
Recent  17403 11291 6477185 
- 222 $ /LY 
- 154 $ /QALY 
Old  16614 10159 5428114 
Stage 2 costs 0 30 
Recent  17403 11291 6407416 
1242 $ /LY 
865 $/ QALY 
Old  16614 10159 5530402 
Stage 3 costs 100 70 
Recent 17403 11291 6525669 
1262 $ /LY 
879 $/ QALY 
Discount rates (d.r.) 
Old  16614 10159 5396037 
Cost d.r. 6% 3% 
Recent 17403 11291 6395968 
1268 $ /LY 
884 $/ QALY 
Old 16860 10348 5460633 
Benefit d.r. 0% 3% 
Recent 17660 11501 6477185 
1271 $ /LY 
881 $/ QALY 
Transition probabilities (t.p.) and assumptions 
Old 16614 7794 5777550 Short-term 
assumption  
No S1 
S1 and 
S2 
Recent 17403 8692 6825439 
1329 $ /LY 
1167 $/ QALY 
Long-term 
t.p. 
See Annex 8 No effect in the short-term part of the model 
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6.10 ANNEX 10: RESULTS OF THE SENSITIVITY ANALYSES FOR THE 
OVERALL MODEL  
Table A10 – Sensitivity analyses results for the overall model (short-term + long-term) using data 
summarized in Annex 8 
Element Values 
varied 
Base 
case 
inputs 
Strate
gy 
LYs 
gained 
QALY
gained 
Costs ICER 
None - Old  49505 29101 13599317 
Base case  
None - Recent  53646 32570 16301437 
653 $/LY 
779 $/QALY 
Costs 
Old  49505 29101 13599317 
487 385 
Recent  53646 32570 19767407 
1490 $ /LY 
1778 $/QALY 
Old  49505 29101 13599317 
527 385 
Recent  53646 32570 21126611 
1818 $ /LY 
2170 $/QALY 
Old  49505 29101 13599317 
Recent 
therapy Drug 
costs 
613 385 
Recent  53646 32570 24048899 
2524 $ /LY 
3013 $/QALY 
Old  49505 29101 15479090 
410 347 
Recent  53646 32570 16301437 
199 $ /LY 
237 $/QALY 
Old  49505 29101 15777467 
420 347 
Recent  53646 32570 16301437 
127 $/ LY 
151 $/QALY 
Old  49505 29101 16195194 
Old therapy 
Drug costs 
434 347 
Recent  53646 32570 16301437 
26 $ /LY 
31 $ /QALY 
Old  49505 29101 13345761 
Stage 2 costs 0 30 
Recent  53646 32570 15963581 
632 $ /LY 
755 $/ QALY 
Old  49505 29101 13919231 
Stage 3 costs 100 70 
Recent 53646 32570 16622888 
653 $ /LY 
779 $/ QALY 
Discount rates (d.r.) 
Old  49505 29101 12564661 
Cost d.r. 6% 3% 
Recent 53646 32570 15056612 
602 $ /LY 
718 $/ QALY 
Old 54821 31945 13599317 
Benefit d.r. 0% 3% 
Recent 59507 35753 16301437 
577 $ /LY 
710 $/ QALY 
Transition probabilities (t.p.) and assumptions 
Old 42516 18872 11479499 
Short-term 
assumptions  
No S1 
improve
ment 
S1 and 
S2 
improv
ement 
Recent 45952 21323 13657901 
634 $ /LY 
889 $/ QALY 
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Annex 10 (continued) 
Element Values 
Varied 
Base 
Case 
inputs 
Strate
gy 
LYs 
gained 
QALY 
gained 
Costs ICER 
Old 46192 24672 11565550 
S1 to 
S1:0.5 
S2 to 
S2:0.50 
S1 to 
S1:0.65 
S2 to 
S2:0.62 Recent 49878 27560 13682026 
574 $ /LY 
733 $/ QALY 
Old 42993 20686 9849923 
Long-term 
t.p. 
 S1 to 
S1:0.20 
S2 to 
S2:0.20 
S1 to 
S1:0.65 
S2 to 
S2:0.62 Recent 46197 23004 11428233 
493 $ /LY 
681 $/ QALY 
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